Jul 2, 2024 - Economy
Charted: Weight-loss drug prices catch heat
Add Axios as your preferred source to
see more of our stories on Google.
Eli Lilly and Novo Nordisk today took a shot across the bow from President Biden and Sen. Bernie Sanders on their pricing of popular GLP-1 drugs.
Driving the news: In an op-ed in USA Today, Biden and Sanders took specific aim at Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro, threatening to take action if the drugmakers didn't lower prices for the popular weight loss and Type-2 diabetes drugs.
- Though they didn't say what specific action they would take, they lobbied for Congress to expand the list of prescription drugs up for price negotiation with the U.S. government.
The bottom line: Both companies have capitalized on the drugs' enormous popularity.
